Prostate cancer vaccine Gonaxin - Zonagen

Drug Profile

Prostate cancer vaccine Gonaxin - Zonagen

Alternative Names: Gonaxin

Latest Information Update: 15 Sep 2003

Price : $50

At a glance

  • Originator Repros Therapeutics
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 31 Dec 2002 Discontinued - Preclinical for Prostate cancer in USA (unspecified route)
  • 18 Dec 2000 New profile
  • 18 Dec 2000 Preclinical development for Prostate cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top